April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Gene Expression Profiling and Regression Rate of Irradiated Uveal Melanomas
Author Affiliations & Notes
  • Rajesh C. Rao
    Ophthalmology & Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI
    Pathology, University of Michigan, Ann Arbor, MI
  • Shahed N Badiyan
    Radiation Oncology, Washington University School of Medicine, St. Louis, MO
  • J William Harbour
    Ocular Oncology Service, Ophthalmology, Bascom Palmer Eye Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
  • Footnotes
    Commercial Relationships Rajesh Rao, None; Shahed Badiyan, None; J William Harbour, Castle Biosciences (C), Castle Biosciences (I), Castle Biosciences (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5091. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rajesh C. Rao, Shahed N Badiyan, J William Harbour; Gene Expression Profiling and Regression Rate of Irradiated Uveal Melanomas. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5091.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To determine whether gene expression profiling (GEP) is associated with rate of tumor regression following I-125 plaque brachytherapy for posterior uveal melanoma.


Retrospective review of of 83 patients with posterior uveal melanoma treated with I-125 plaque brachytherapy in which GEP class and 3-month post-radiation ultrasonographic tumor thickness were available. Recorded data included baseline patient and tumor characteristics and tumor thickness at 3-months after treatment. Statistical analysis was performed using T-test and Fischer’s exact test.


GEP class assignment was class 1 in 83 (60.1%) and class 2 in 55 (39.9%) of patients. Mean patient age was 60.9 years for class 1 and 68.1 years for class 2 tumors (P=0.002). Mean initial tumor diameter was 13.0 mm for class 1 and 14.1 mm for class 2 tumors (P=0.02). Mean initial tumor thickness was 5.3 mm for class 1 and 6.1 mm for class 2 tumors (P=0.09). Mean reduction in tumor thickness at 3-month post-radiation 26.5% for class 1 and 13.0% for class 2 tumors (P=0.01). Complete tumor regression with flat residual tumor was observed for four class 1 tumors and no class 2 tumors.


Class 1 tumors exhibit more rapid early tumor regression than class 2 tumors following I-125 plaque radiotherapy. This observation may reflect molecular and/or immunologic differences between the two tumor classes.

Keywords: 744 tumors • 533 gene/expression • 639 pathology techniques  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.